Team member Oncodrone
Team member Oncodrone

Henk Viƫtor
Chief Executive Officer

Team member Oncodrone

Johan Tijhuis
non-executive

Team member Oncodrone

Antoine Wellink
Director Drug Development

Prof. Dr. Jack Schalken [1959]
Chief Scientific Officer

Jack Schalken obtained his M.Sc. and Ph.D. in Biochemistry at Radboud UMC in Nijmegen. He holds a professorship in Experimental Urology and is research director at RUMC (Nijmegen, The Netherlands).

He is renowned for his expertise on the molecular basis of (therapy resistant) prostate cancer and is a board member of international scientific organizations including the European Society for Urological Research (ESUR).

Jack is experienced in coordinating large multi-centered prostate cancer research programs. He led the team that developed the PCA3 prostate cancer test and is co-founder/ CSO at Noviogendix, a spin-off company from RUMC, offering molecular diagnostics for GU cancer.